The contribution of asymptomatic SARS-CoV-2 infections to transmission on the Diamond Princess cruise ship
© 2020, Emery et al..
A key unknown for SARS-CoV-2 is how asymptomatic infections contribute to transmission. We used a transmission model with asymptomatic and presymptomatic states, calibrated to data on disease onset and test frequency from the Diamond Princess cruise ship outbreak, to quantify the contribution of asymptomatic infections to transmission. The model estimated that 74% (70-78%, 95% posterior interval) of infections proceeded asymptomatically. Despite intense testing, 53% (51-56%) of infections remained undetected, most of them asymptomatic. Asymptomatic individuals were the source for 69% (20-85%) of all infections. The data did not allow identification of the infectiousness of asymptomatic infections, however low ranges (0-25%) required a net reproduction number for individuals progressing through presymptomatic and symptomatic stages of at least 15. Asymptomatic SARS-CoV-2 infections may contribute substantially to transmission. Control measures, and models projecting their potential impact, need to look beyond the symptomatic cases if they are to understand and address ongoing transmission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
eLife - 9(2020) vom: 24. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emery, Jon C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asymptomatic infections |
|---|
| Anmerkungen: |
Date Completed 19.10.2020 Date Revised 16.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7554/eLife.58699 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314047859 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314047859 | ||
| 003 | DE-627 | ||
| 005 | 20240216232058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.58699 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM314047859 | ||
| 035 | |a (NLM)32831176 | ||
| 035 | |a (PII)e58699 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Emery, Jon C |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The contribution of asymptomatic SARS-CoV-2 infections to transmission on the Diamond Princess cruise ship |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2020 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020, Emery et al. | ||
| 520 | |a A key unknown for SARS-CoV-2 is how asymptomatic infections contribute to transmission. We used a transmission model with asymptomatic and presymptomatic states, calibrated to data on disease onset and test frequency from the Diamond Princess cruise ship outbreak, to quantify the contribution of asymptomatic infections to transmission. The model estimated that 74% (70-78%, 95% posterior interval) of infections proceeded asymptomatically. Despite intense testing, 53% (51-56%) of infections remained undetected, most of them asymptomatic. Asymptomatic individuals were the source for 69% (20-85%) of all infections. The data did not allow identification of the infectiousness of asymptomatic infections, however low ranges (0-25%) required a net reproduction number for individuals progressing through presymptomatic and symptomatic stages of at least 15. Asymptomatic SARS-CoV-2 infections may contribute substantially to transmission. Control measures, and models projecting their potential impact, need to look beyond the symptomatic cases if they are to understand and address ongoing transmission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a asymptomatic infections | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a human | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a microbiology | |
| 650 | 4 | |a subclinical infections | |
| 650 | 4 | |a transmission | |
| 700 | 1 | |a Russell, Timothy W |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Hellewell, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Carl Ab |e verfasserin |4 aut | |
| 700 | 0 | |a CMMID COVID-19 Working Group |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Gwenan M |e verfasserin |4 aut | |
| 700 | 1 | |a Eggo, Rosalind M |e verfasserin |4 aut | |
| 700 | 1 | |a Kucharski, Adam J |e verfasserin |4 aut | |
| 700 | 1 | |a Funk, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Flasche, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Houben, Rein Mgj |e verfasserin |4 aut | |
| 700 | 1 | |a Atkins, Katherine E |e investigator |4 oth | |
| 700 | 1 | |a Klepac, Petra |e investigator |4 oth | |
| 700 | 1 | |a Endo, Akira |e investigator |4 oth | |
| 700 | 1 | |a Jarvis, Christopher I |e investigator |4 oth | |
| 700 | 1 | |a Davies, Nicholas G |e investigator |4 oth | |
| 700 | 1 | |a Rees, Eleanor M |e investigator |4 oth | |
| 700 | 1 | |a Meakin, Sophie R |e investigator |4 oth | |
| 700 | 1 | |a Rosello, Alicia |e investigator |4 oth | |
| 700 | 1 | |a van Zandvoort, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Munday, James D |e investigator |4 oth | |
| 700 | 1 | |a Edmunds, W John |e investigator |4 oth | |
| 700 | 1 | |a Jombart, Thibaut |e investigator |4 oth | |
| 700 | 1 | |a Auzenbergs, Megan |e investigator |4 oth | |
| 700 | 1 | |a Nightingale, Emily S |e investigator |4 oth | |
| 700 | 1 | |a Jit, Mark |e investigator |4 oth | |
| 700 | 1 | |a Abbott, Sam |e investigator |4 oth | |
| 700 | 1 | |a Simons, David |e investigator |4 oth | |
| 700 | 1 | |a Bosse, Nikos I |e investigator |4 oth | |
| 700 | 1 | |a Leclerc, Quentin J |e investigator |4 oth | |
| 700 | 1 | |a Procter, Simon R |e investigator |4 oth | |
| 700 | 1 | |a Villabona-Arenas, C Julian |e investigator |4 oth | |
| 700 | 1 | |a Tully, Damien C |e investigator |4 oth | |
| 700 | 1 | |a Deol, Arminder K |e investigator |4 oth | |
| 700 | 1 | |a Sun, Fiona Yueqian |e investigator |4 oth | |
| 700 | 1 | |a Hué, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Foss, Anna M |e investigator |4 oth | |
| 700 | 1 | |a Prem, Kiesha |e investigator |4 oth | |
| 700 | 1 | |a Medley, Graham |e investigator |4 oth | |
| 700 | 1 | |a Gimma, Amy |e investigator |4 oth | |
| 700 | 1 | |a Lowe, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Clifford, Samuel |e investigator |4 oth | |
| 700 | 1 | |a Quaife, Matthew |e investigator |4 oth | |
| 700 | 1 | |a Diamond, Charlie |e investigator |4 oth | |
| 700 | 1 | |a Gibbs, Hamish P |e investigator |4 oth | |
| 700 | 1 | |a Quilty, Billy J |e investigator |4 oth | |
| 700 | 1 | |a OReilly, Kathleen |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t eLife |d 2012 |g 9(2020) vom: 24. Aug. |w (DE-627)NLM221831460 |x 2050-084X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g day:24 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7554/eLife.58699 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |b 24 |c 08 | ||